AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Calcium/calmodulin-dependent protein kinase type 1G

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.

Our library stands out due to several important features:

  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q96NX5

UPID:

KCC1G_HUMAN

Alternative names:

CaM kinase I gamma; CaMK-like CREB kinase III

Alternative UPACC:

Q96NX5; Q86UH5; Q9Y3J7

Background:

Calcium/calmodulin-dependent protein kinase type 1G, also known as CaM kinase I gamma and CaMK-like CREB kinase III, plays a pivotal role in a proposed calcium-triggered signaling cascade. This kinase, identified by the accession number Q96NX5, is known to phosphorylate transcription factor CREB1 in vitro, suggesting its involvement in the regulation of gene expression.

Therapeutic significance:

Understanding the role of Calcium/calmodulin-dependent protein kinase type 1G could open doors to potential therapeutic strategies. Its involvement in phosphorylating CREB1 highlights its significance in cellular signaling pathways, which could be targeted in various therapeutic contexts.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.